Las enfermedades cardiovasculares y el Covid-19: una relación de muerte
Cardiovascular disease and Covid-19: a relationship of mortality
Resumen
Abstract
Bibliografía
1. Naranjo-Dominguez A, Valdés A. COVID-19. Punto de vistadel cardiólogo.2020;26(1): 1-5.
2. Kunal S, Gupta K, Sharma SM, Pathak V, Mittal S, Tarke C.Cardiovascular system and COVID-19: perspectives from adeveloping country. Monaldi Arch Chest Dis. 2020 May 7;90(2).
3. Kochi AN, Tagliari AP, Forleo GB, Fassini GM, Tondo C. Cardiac and arrhythmic complications in patients with COVID-19. JCardiovasc Electrophysiol. 2020 May;31(5):1003-1008
4. gob.mx[Internet]. México: Secretaria de salud2020[actualizado 20 May 2020; citado 20 may 2020].Disponible en: https://covid19.sinave.gob.mx/
5. Triana JFF, Márquez DAS, Silva JSC, Castro CCA, SandovalAFB. COVID-19 y enfermedad cardiovascular. RevColombCardiol. 2020; 27(3): 166-174.
6. Sanders JM, Monogue ML,. Jodlowski TZ, Cutrell JB.Pharmacologic Treatments for Coronavirus Disease 2019(COVID-19). JAMA. 2020;323(18):1824-1836.
7. Wu Z, McGoogan JM. Characteristics of and ImportantLessons From the Coronavirus Disease 2019 (COVID-19)Outbreak in China: Summary of a Report of 72 314 CasesFrom the Chinese Center for Disease Control and Prevention. JAMA. 2020; 323(13): 1239-1242.
8. Bansal M. Cardiovascular Disease and COVID-19. DiabetesMetab Syndr. May-Jun 2020;14(3):247-250.
9. Akhmerov A, Marbán E. COVID-19 and the Heart. Circ Res.2020 May 8;126(10):1443-1455.
10. Clerkin KJ, Fried JA, Raikhelkar J, Sayer G, Griffin JM,Masoumi A.COVID-19 and Cardiovascular Disease. Circulation.2020 May 19;141(20):1648-1655.
11. Nunes A, Tagliari AP, Battista G, Michele G, Tondo C. Cardiacand Arrhythmic Complications in Patients With COVID-19. JCardiovasc Electrophysiol. 2020 May;31(5):1003-1008.
12. Guzik TJ, Mohiddin SA, Dimarco A, Patel V, Savvatis K,Marelli-Berg FM. COVID-19 and the Cardiovascular System:Implications for Risk Assessment, Diagnosis, and TreatmentOptions. Cardiovasc Res. 2020; 116(10): 1666-1687.
13. Aghagoli G, Gallo B, Soliman LB, Sellke FW. CardiacInvolvement in COVID-19 Patients: Risk Factors, Predictors,and Complications: A Review. J Card Surg. 2020; 35(6):1302-1305.
14. Li B, Yang J, Zhao F, Zhi L, Wang X, Liu L. Prevalence andImpact of Cardiovascular Metabolic Diseases on COVID-19 inChina. Clin Res Cardiol. 2020 May;109(5):531-538.
15. Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN. Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19. N Engl JMed. 2020; 382(25): e102.
16. South AM, Diz DI, Chappell MC. COVID-19, ACE2, and thecardiovascular consequences. Am J Physiol Heart CircPhysiol. 2020;318(5):H1084-H1090.
17. Kang Y, Chen T, Mui D, Ferrari V, Jagasia D. Covascularmanifestations and treatment considerations in COVID-19.Heart. 2020; 106(15): 1132-1141.
18. Pastick KA, Okafor EC, Wang F, Lofgren SM, Skipper CP,Nicol MR. Review: Hydroxychloroquine and Chloroquine forTreatment of SARS-CoV-2 (COVID-19). Open Forum Infect Dis.2020;7(4): ofaa130.
19. Zhu H, Rhee JW, Cheng P, et al. Cardiovascular Complications in Patients with COVID-19: Consequences of Viral Toxicitiesand Host Immune Response [published correction appearsin Curr Cardiol Rep. 2020 May 13;22(5):36]. Curr Cardiol Rep.2020;22(5):32.
20. Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and thecardiovascular system. Nat Rev Cardiol. 2020;17(5):259-260.
21. Guo T, Fan Y, Chen M, et al. Cardiovascular Implications ofFatal Outcomes of Patients With Coronavirus Disease 2019(COVID-19).JAMA Cardiol. 2020; 5(7): 811-818.
22. Zheng Z, Peng F, Xu B, Zhao J, Liu H, Pung J, et al. Risk factors of critical & mortalCOVID-19 cases: A systematic literature review and meta-analysisJInfect. 2020; 81(2): e16-e25
- Resumen visto - 708 veces
- PDF descargado - 24 veces